What is H.C. Wainwright's price target for FATE?

H.C. Wainwright's latest stated price target for Fate Therapeutics Inc. (FATE) is $5, from its action on Oct 31, 2025.

What is H.C. Wainwright's rating on FATE?

H.C. Wainwright rates FATE Buy, a bullish rating, as of Oct 31, 2025.

When did H.C. Wainwright last change its view on FATE?

On Oct 31, 2025, H.C. Wainwright upgrades to Buy from Neutral, price target $5.

H.C. Wainwright FATE price target and rating history

Fate Therapeutics Inc. (FATE) · Health Care

H.C. Wainwright rates Fate Therapeutics Inc. (FATE) Buy with a $5 price target, as of its latest action on Oct 31, 2025. It has published 5 rating actions on FATE since August 2021, including 1 upgrade and 1 downgrade.

Current rating: Buy
Price target: $5
Median target, all firms: Too few
Actions on FATE: 5

H.C. Wainwright price target on FATE

H.C. Wainwright price target on FATE, each point a stated target, August 2021 to October 2025.

Every H.C. Wainwright rating on FATE

Oct 31, 2025
UpgradeH.C. Wainwright upgrades to Buy from Neutral, price target $5
Jan 24, 2023
DowngradeH.C. Wainwright downgrades to Neutral from Buy, price target $115 to $7
Mar 4, 2022
ReiterateH.C. Wainwright cuts its price target to $115 from $122, keeps Buy
Dec 15, 2021
ReiterateH.C. Wainwright raises its price target to $122 from $121, keeps Buy
Aug 5, 2021
ReiterateH.C. Wainwright raises its price target to $121 from $120, keeps Buy

Questions about H.C. Wainwright and FATE

What is H.C. Wainwright's price target for FATE?: H.C. Wainwright's latest stated price target for Fate Therapeutics Inc. (FATE) is $5, from its action on Oct 31, 2025.
What is H.C. Wainwright's rating on FATE?: H.C. Wainwright rates FATE Buy, a bullish rating, as of Oct 31, 2025.
When did H.C. Wainwright last change its view on FATE?: On Oct 31, 2025, H.C. Wainwright upgrades to Buy from Neutral, price target $5.

More FATE rating histories

All H.C. Wainwright ratings FATE news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.